Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, an

Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.
Market Dynamics
Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.
Key features of the study:
This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.
Detailed Segmentation:
Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Global Plasma Protease C1-inhibitor Treatment Market, By Dosage:
Lyophilized
Injectable
Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Plasma Protease C1-inhibitor Treatment Market, By Region:
North America
By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage:
Lyophilized
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage:
Lyophilized
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage:
Lyophilized
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage:
Lyophilized
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage:
Lyophilized
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage:
Lyophilized
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles:
CSL Behring LLC *
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Takeda Pharmaceutical Company Limited
Ionis Pharmaceuticals, Inc.
Pharming Technologies B.V.
Centogene AG
BioCryst Pharmaceuticals
KalVista Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.